Corticoid-associated complications in elderly

##plugins.themes.academic_pro.article.sidebar##

Published Nov 23, 2012
Download
pdf
Vol. 90 No. 11 (2012): Issue Nov 2012

##plugins.themes.academic_pro.article.main##

Besma Ben Dhaou
Fatma Boussema
Zohra Aydi
Lilia Baili
Hédi Tira
Ouahida Cherif
Lilia Rokbani

Abstract

Background: Corticosteroids are widely prescribed products in the elderly particularly in systemic diseases. Corticosteroids were indispensable in controlling a variety of disease states. Various complications associated with this drug class warrant caution and monitoring with each formulation especially with old population.
Aim: To evaluate the frequency and type of side effects and complications of long-term corticosteroid therapy in the elderly.
Methods:We conducted a retrospective study of 23 patients aged 65 and older hospitalized in the internal medicine department of the Habib Thameur hospital during January 2000 to December 2004. Corticoid adverse effects were recorded throughout the follow up period.
Results: There are 20 women and 3 men aged 66 to 87 years with a mean age of 75.7 years. The diagnoses were 8 cases of temporal arteritis, 7 cases of rheumatoid arthritis, 3 cases of multiple myeloma, 2 scleroderma, 1 case of systemic lupus erythematosus, 1 case of retroperitoneal fibrosis and 1 case of psoriatic arthritis. We selected 66 complications. Infectious complications were found in 26 cases (39.3%), 11 cases (16.7%) of iatrogenic diabetes, arterial hypertension in 9 cases (13%), skeletal complications in both cases,psychiatric complications in two cases, ophthalmologic complications in one case.
Conclusion: Despite lifestyle rules and adjunctive therapy, complications seem to be frequent. To minimize the disadvantages of prolonged corticosteroid treatment, regular monitoring and careful screening is imperative for the support and time.

Keywords:

Side effects - Complications - steroids - elderly

##plugins.themes.academic_pro.article.details##

References

  1. Amoura Z, Amoura I, Bletry O. Connectivites. Encyc. Med. Chir. Thérapeutique 1994; 25-165-A-10: 1-12.
  2. Chevalet P, Barrier JH, Glémarec J et al. Maladie de Horton de plus de 75 ans : particularités évolutives, complications de la corticothérapie. Etude comparative sur une série de 164 patientes. Vers une dose d'attaque réduite. Rev Med Interne 2001; 22: 624- 30.
  3. American College of rheumatology task force on osteoporosis guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996: 39: 1791-801.
  4. Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM. La polyarthrite rhumatoïde du sujet âgé. Rev Rhum 2010; 77: 326-32.
  5. Treves R, Bertin P. La corticothérapie au cours de la polyarthrite rhumatoïde. Ann Med Interne 2002 ; 153 : 53-60.
  6. Cohen P, Guillevin L. la corticothérapie au cours des maladies systémiques. Ann Med Interne 1994 ; 145 : 23-28.
  7. Gaujard S, Broussolle C, Cathebras P, et al. Lupus érythémateux disséminé survenant après 65 ans. Rev Med Interne 2003 ; 24 : 288-94.
  8. Agard C, Barrier JH. La maladie de Horton simple : modalités thérapeutiques. Presse Med 2004 ; 33 : 41-50.
  9. Delauche-Cavallier MC. Pseudo polyarthrite rhizomélique et maladie de Horton. Encycl Med Chir Thérapeutique. 1987 ; 25171-A10 : 1-6.
  10. Henzen C. Traitement aux glucocorticoïdes : risques et effets secondaires. Form Med Suisse 2003 ; 19 : 442-46.
  11. Orcel G. Ostéoporose cortisonique : nouvelles approches. Rhumatologie 1997 ; 66 : 717-26.
  12. Fauchais AL, Boivin H, Hachulla E et al. Complications psychiatriques de la corticothérapie chez le sujet âgé de plus de 65 ans traité pour maladie de Horton. Rev Med Interne 2002 ; 23 : 828-33.
  13. Rozenberg S. Corticoïdes et pathologie rachidienne lombaire commune. Rev Rhum 1998 ; 65 : 719-26.
  14. Larbre JP, Lorca G. Corticostéroïdes : principe et règles d'utilisation. Rev Prat 1999 ; 49 : 893-898.